Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Fresh approach to AMR

Posted 22 July 2021 AM

The Westmead Institute for Medical Research is gearing up to conduct a first-in-human trial of genetically modified (GM) gut bacteria to reduce antibiotic resistance after receiving the green-light from the Office of the Gene Technology Regulator (OGTR).

The proposed trial is designed to evaluate the safety and efficacy of GM E.coli (Nissle strain) - a widely used probiotic - to deliver genes to gut bacteria that restore sensitivity to antibiotics.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pitfalls may plague NMP review
With an election in play, will it arrive too late?
Approvals Action
First copy of Halaven ticked
Along with other generics of already PBS-listed drugs